Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes

Diabetes Care
Mette ZanderJ J Holst

Abstract

The incretin hormone glucagon-like peptide-1 (GLP-1) reduces plasma glucose in type 2 diabetic patients by stimulating insulin secretion and inhibiting glucagon secretion. The biguanide metformin is believed to lower plasma glucose without affecting insulin secretion. We conducted this study to investigate the effect of a combination therapy with GLP-1 and metformin, which could theoretically be additive, in type 2 diabetic patients. In a semiblinded randomized crossover study, seven patients received treatment with metformin (1,500 mg daily orally) alternating with GLP-1 (continuous subcutaneous infusion of 2.4 pmol x kg(-1) x min(-1)) alternating with a combination of metformin and GLP-1 for 48 h. Under fixed energy intake, we examined the effects on plasma glucose, insulin, C-peptide, glucagon, and appetite. Fasting plasma glucose (day 2) decreased from 13.9 +/- 1 (no treatment) to 11.2 +/- 0.4 (metformin) and 11.5 +/- 0.5 (GLP-1) and further decreased to 9.4 +/- 0.7 (combination therapy) (P = 0.0005, no difference between monotherapy with GLP-1 and metformin). The 24-h mean plasma glucose (day 2) decreased from 11.8 +/- 0.5 (metformin) and 11.7 +/- 0.8 (GLP-1) to 9.8 +/- 0.5 (combination) (P = 0.02, no difference between GL...Continue Reading

References

Aug 31, 1995·The New England Journal of Medicine·M StumvollJ E Gerich
Jan 1, 1996·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·U PantenC Schwanstecher
Jul 7, 1999·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·H C Howlett, C J Bailey
Aug 24, 1999·Annals of Internal Medicine·R A DeFronzo

❮ Previous
Next ❯

Citations

Nov 7, 2002·Biochemical and Biophysical Research Communications·Nobuyuki YasudaIsao Tanaka
Oct 24, 2002·Advanced Drug Delivery Reviews·James M Lenhard, William K Gottschalk
Dec 25, 2003·Drug Discovery Today·Rob Hooft
Jul 6, 2013·Experimental & Molecular Medicine·Tae Jung OhYoung Min Cho
Dec 1, 2004·Basic & Clinical Pharmacology & Toxicology·Jesper GromadaPatrik Rorsman
Mar 16, 2005·Treatments in Endocrinology·Laurie L Baggio, Daniel J Drucker
Dec 11, 2013·The Journal of Endocrinology·L van BloemendaalM Diamant
Jan 30, 2016·Nature Reviews. Drug Discovery·Da Young Oh, Jerrold M Olefsky
Sep 24, 2005·Annals of Medicine·C Mark B Edwards
Feb 16, 2010·Nutrition·David P BradleyDale A Schoeller
Apr 22, 2005·Diabetic Medicine : a Journal of the British Diabetic Association·J R LindsayP M Bell
May 11, 2007·Diabetes, Obesity & Metabolism·D MaggsM A Nauck
Mar 23, 2005·Regulatory Peptides·Michael A Nauck, Juris J Meier
Nov 21, 2007·Brain Research·Niels VrangMads Tang-Christensen
Apr 28, 2004·Diabetes Care·Zachary T Bloomgarden
Jul 30, 2002·Diabetes Care·Simon A HinkeHans-Ulrich Demuth
Sep 30, 2003·Diabetes Care·Daniel J Drucker
May 11, 2016·Cell Reports·Adam R KonopkaK Sreekumaran Nair
Dec 29, 2011·The Annals of Pharmacotherapy·Nicole R PinelliDenise H Rhoney
Nov 12, 2003·The Journal of Biological Chemistry·Simon A HinkeChristopher H S McIntosh
Apr 26, 2003·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Niels VrangHans-Rudolf Berthoud

❮ Previous
Next ❯

Related Concepts

Related Feeds

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.